-
MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of patients with B-cell malignancies.
-
The Leukemia & Lymphoma Society (LLS) continues to lead cutting-edge research to advance treatments for myeloma and lymphoma. Adding to the momentum, the organization announced a $1,175,000 commitment by the Schwartz Ward Family Foundation (SWFF) of Chicago to support two unique research initiatives including a novel therapy for a rare form of lymphoma and an innovative immunotherapy approach for multiple myeloma.